Lyndon Marc Evans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7502078/publications.pdf

Version: 2024-02-01

97 papers	2,500 citations	172207 29 h-index	223531 46 g-index
100 all docs	100 docs citations	100 times ranked	2994 citing authors

#	Article	IF	Citations
1	A Narrative Review of ChronicÂKidneyÂDisease in Clinical Practice: Current Challenges and Future Perspectives. Advances in Therapy, 2022, 39, 33-43.	1.3	57
2	Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes, Obesity and Metabolism, 2022, 24, 377-390.	2.2	23
3	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. Diabetes Therapy, 2022, 13, 241-250.	1.2	11
4	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. Vaccines, 2022, 10, 140.	2.1	7
5	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy, 2022, 13, 225-240.	1.2	4
6	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872.	1.2	5
7	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy, 2022, 13, 889-911.	1.2	2
8	Healthcare costs and hospitalizations in <scp>US</scp> patients with type 2 diabetes and cardiovascular disease: A retrospective database study (<scp>OFFSET</scp>). Diabetes, Obesity and Metabolism, 2022, 24, 1300-1309.	2.2	7
9	Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. CKJ: Clinical Kidney Journal, 2022, 15, 758-770.	1.4	5
10	New Therapeutic Horizons in ChronicÂKidneyÂDisease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs, 2022, 82, 97-108.	4.9	4
11	Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. Diabetes Therapy, 2021, 12, 87-105.	1.2	17
12	Sodium-Glucose Co-TransporterÂ2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials. Diabetes Therapy, 2021, 12, 55-70.	1.2	22
13	Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review. Advances in Therapy, 2021, 38, 994-1010.	1.3	22
14	One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 1593-1604.	1.2	3
15	A populationâ€adjusted indirect comparison of cardiovascular benefits of onceâ€weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinology, Diabetes and Metabolism, 2021, 4, e00259.	1.0	8
16	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255.	4.9	2
17	The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes. Diabetes Therapy, 2021, 12, 2817-2826.	1.2	1
18	Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example. Vaccines, 2021, 9, 1180.	2.1	18

#	Article	IF	Citations
19	An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK . Diabet Med 2019; 36: 1063â€“1071. Diabetic Medicine, 2020, 37, 1405-1407.	1.2	0
20	Systematic literature review and network metaâ€analysis of sodiumâ€glucose coâ€transporter inhibitors vs metformin as addâ€on to insulin in type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 39-50.	2.2	8
21	Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials. Diabetes Therapy, 2020, 11, 369-386.	1.2	48
22	Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes. Diabetes Therapy, 2020, 11, 37-52.	1.2	29
23	Diabetes and Novel Coronavirus Infection: Implications for Treatment. Diabetes Therapy, 2020, 11, 1915-1924.	1.2	6
24	Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Therapy, 2020, 11, 1925-1934.	1.2	15
25	Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies. Diabetes Therapy, 2020, 11, 2221-2235.	1.2	14
26	A look to the future in nonâ€alcoholic fatty liver disease: Are glucagonâ€like peptideâ€1 analogues or sodiumâ€glucose coâ€transporterâ€2 inhibitors the answer?. Diabetes, Obesity and Metabolism, 2020, 22, 2227-2240.	2.2	14
27	Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?. Diabetes Therapy, 2020, 11, 2207-2219.	1.2	41
28	What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient. Diabetes Therapy, 2020, 11, 1381-1395.	1.2	4
29	Costâ€effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, Obesity and Metabolism, 2020, 22, 1047-1055.	2.2	6
30	Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs, 2020, 80, 147-165.	4.9	13
31	Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial. Advances in Therapy, 2020, 37, 2413-2426.	1.3	9
32	Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Therapy, 2020, 11, 1199-1216.	1.2	123
33	SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 2757-2774.	1.2	20
34	What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. Diabetes Therapy, 2019, 10, 1719-1731.	1.2	5
35	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1câ€”Translating Evidence into Practice. Diabetes Therapy, 2019, 10, 1595-1622.	1.2	36
36	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabetic Medicine, 2019, 36, 1063-1071.	1.2	8

#	Article	IF	Citations
37	Realâ€World Associations of Reninâ€“Angiotensinâ€“Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With Newâ€Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. Journal of the American Heart Association, 2019, 8, e012655.	1.6	44
38	Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21Â334 patients in the UK. ESC Heart Failure, 2019, 6, 280-290.	1.4	57
39	Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. Diabetes Therapy, 2019, 10, 1793-1800.	1.2	11
40	The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrology, 2019, 20, 31.	0.8	24
41	A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019. Diabetes Therapy, 2019, 10, 1-3.	1.2	3
42	Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes, Obesity and Metabolism, 2019, 21, 467-478.	2.2	110
43	Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA_{1c}, weight and hypoglycaemic event incidence. Diabetic Medicine, 2018, 35, 557-566.	1.2	14
44	An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. Journal of Medical Economics, 2018, 21, 340-347.	1.0	24
45	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2018, 9, 27-36.	1.2	5
46	P1810The association between renin-angiotensin-aldosterone system inhibitors dose reduction and risk of mortality and major adverse cardiovascular events in heart failure patients. European Heart Journal, 2018, 39, .	1.0	0
47	FP371RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i157-i157.	0.4	0
48	FP337RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i145-i145.	0.4	1
49	Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Research and Care, 2018, 6, e000512.	1.2	37
50	P5671Real-world dosing of renin-angiotensin-aldosterone system inhibitors in heart failure patients, and associations between hyperkalaemia and down-titration or discontinuation. European Heart Journal, 2018, 39, .	1.0	0
51	Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. Journal of Medical Economics, 2018, 21, 1172-1182.	1.0	5
52	Living with Type 2 Diabetes: Patient Commentary in Response to the Paper â€˜SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practiceâ€™. Diabetes Therapy, 2018, 9, 1729-1732.	1.2	1
53	SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Therapy, 2018, 9, 1757-1773.	1.2	53
54	Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrology, 2018, 19, 211.	0.8	34

#	Article	IF	Citations
55	Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy, 2018, 9, 1919-1930.	1.2	14
56	Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes. Diabetes, 2018, 67, .	0.3	7
57	Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. Diabetes Therapy, 2017, 8, 275-291.	1.2	26
58	Managing glycaemia in older people with type 2 diabetes: <scp>A</scp> retrospective, primary careâ€based cohort study, with economic assessment of patient outcomes. Diabetes, Obesity and Metabolism, 2017, 19, 644-653.	2.2	16
59	An alternative approach to modelling <scp>HbA1c</scp> trajectories in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 628-634.	2.2	5
60	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. Diabetes Therapy, 2017, 8, 1175-1185.	1.2	3
61	Clinical Safety and Tolerability of Vildagliptin â€“ Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. European Endocrinology, 2017, 13, 68.	0.8	23
62	Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus. Vascular Health and Risk Management, 2016, Volume 12, 337-340.	1.0	21
63	Practical Approaches to Diabetes Care: An Introduction. Diabetes Therapy, 2016, 7, 377-377.	1.2	0
64	Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. Diabetes Therapy, 2016, 7, 809-823.	1.2	4
65	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse Î²-cell function in the GetGoal-M and GetGoal-S trials. Journal of Diabetes and Its Complications, 2016, 30, 1385-1392.	1.2	15
66	Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health and Quality of Life Outcomes, 2016, 14, 13.	1.0	24
67	Hypoglycemia, diabetes therapies and driving categories in type 2 diabetes. Current Medical Research and Opinion, 2016, 32, 1005-1012.	0.9	3
68	A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2016, 11, 217-232.	1.2	4
69	Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24â€week, randomized, openâ€label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (<scp>L</scp>anScape). Diabetes, Obesity and Metabolism, 2015, 17, 1133-1141.	2.2	39
70	Approach to assessing the economic impact of insulinâ€related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool. Diabetic Medicine, 2015, 32, 1156-1166.	1.2	21
71	Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Research and Care, 2015, 3, e000057.	1.2	34
72	Clinical use of insulin degludec. Diabetes Research and Clinical Practice, 2015, 109, 19-31.	1.1	56

#	Article	IF	Citations
73	Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. Journal of Medical Economics, 2015, 18, 56-68.	1.0	32
74	Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?. Diabetes Therapy, 2015, 6, 1-5.	1.2	4
75	Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy. Diabetes Therapy, 2015, 6, 495-507.	1.2	3
76	Cardiovascular and heart failure safety profile of vildagliptin: a metaâ€analysis of 17â€‰000 patients. Diabetes, Obesity and Metabolism, 2015, 17, 1085-1092.	2.2	89
77	Clinical and costâ€“effectiveness of insulin degludec: from clinical trials to clinical practice. Journal of Comparative Effectiveness Research, 2015, 4, 279-286.	0.6	3
78	Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practiceâ€”a case-based evaluation. Journal of Medical Economics, 2015, 18, 96-105.	1.0	23
79	Costâ€effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulinÂâ€“Âfrom the <scp>UK</scp> health care cost perspective. Diabetes, Obesity and Metabolism, 2014, 16, 366-375.	2.2	40
80	Factors Associated With Weight Gain and Hypoglycaemia and The Impact Upon Hospitalisation in Type 2 Diabetes Patients Managed With Metformin Plus Sulphonylurea. Value in Health, 2014, 17, A360.	0.1	0
81	Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health and Quality of Life Outcomes, 2013, 11, 90.	1.0	142
82	A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice. Diabetes Therapy, 2013, 4, 27-40.	1.2	37
83	Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom. Diabetes Therapy, 2013, 4, 51-66.	1.2	9
84	A comparison of healthâ€related quality of life (health utility) between insulin degludec and insulin glargine: a metaâ€analysis of phase 3 trials. Diabetes, Obesity and Metabolism, 2013, 15, 564-571.	2.2	30
85	Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. Journal of Medical Economics, 2013, 16, 1357-1365.	1.0	38
86	Lixisenatide as add-on therapy to basal insulin. Drug Design, Development and Therapy, 2013, 8, 25.	2.0	6
87	Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Preference and Adherence, 2013, 7, 925.	0.8	28
88	Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrology Dialysis Transplantation, 2012, 27, 2255-2263.	0.4	40
89	A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism, 2011, 13, 677-684.	2.2	122
90	Letter from the Editor. Diabetes Therapy, 2010, 1, 1-1.	1.2	2

#	Article	IF	Citations
91	Understanding the interâ€relationship between improved glycaemic control, hypoglycaemia and weight change within a longâ€term economic model. Diabetes, Obesity and Metabolism, 2010, 12, 431-436.	2.2	34
92	Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. European Journal of Clinical Investigation, 2003, 33, 231-238.	1.7	47
93	The future direction of cholesterol-lowering therapy. Current Opinion in Lipidology, 2002, 13, 663-669.	1.2	24
94	The myotoxicity of statins. Current Opinion in Lipidology, 2002, 13, 415-420.	1.2	95
95	Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle. Drug Safety, 2002, 25, 649-663.	1.4	184
96	Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E6. Journal of Immunology, 2001, 167, 5420-5428.	0.4	101
97	Haemolytic uraemic syndrome associated with OKT3. Transplant International, 1996, 9, 522-523.	0.8	10